Meet the People Behind DrugCard
Building the Future of Pharmacovigilance
Discover who we are, how DrugCard began, and what drives our mission to make pharmacovigilance faster, safer, and smarter.
Our History
Brothers Artem and Dmytro Horilyk discussed ways to improve pharmacovigilance processes. At the time, Artem worked as a pharmacovigilance specialist, and Dmytro questioned why literature screening was still performed manually. Their friend Myroslav proposed developing code to automate the process.
By August, the team completed the MVP and started reaching out to potential clients.
The company signed its first client in April, followed shortly by one of the largest pharmaceutical companies in the region. In December, DrugCard received its first investments from Spain and Ukraine.
the UK, multinational partnerships.
The first European clients joined from Germany, and the team began monitoring new countries.
The team started training AI models on real pharmacovigilance data and launched a PV service (1 specialist, 1 project, 1 country). By year-end: 10 clients, 30 countries, 10 team members.
The company introduced an LLM model for article categorization and global literature coverage. In December, the AI Case Intake module was released, automatically extracting adverse reaction data from unstructured text. By year-end: 22 team members, 48 clients, 55 countries covered.
DrugCard now operates in 121+ countries, processes over 1 million articles, and provides AI-based global assessment, regulatory intelligence, and safety database solutions. PV services: 3 specialists, 11 projects, and 21 countries.
platform features.
pharmacovigilance. DrugCard turns data chaos into actionable insights, automates article analysis and reporting, and ensures quality control — so experts can focus on strategic decisions and patient safety.
the standard for how AI transforms compliance, safety, and
efficiency across the pharmaceutical industry.
